Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 8/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27938918 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 | |
| SCHEMBL11303507 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 | |
| SCHEMBL15418858 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 | |
| SCHEMBL8442646 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 | |
| SCHEMBL9220001 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 | |
| SCHEMBL10331011 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 | |
| SCHEMBL552425 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 | |
| SCHEMBL10951377 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 | |
| SCHEMBL9224792 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 | |
| SCHEMBL6294472 | 1.00 | KMT2A (0.46) | KMT2ACA1CA2CA9LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4106071-B1 | ELECTROLYTE FOR LITHIUM-SULFUR SECONDARY BATTERY AND LITHIUM-SULFUR SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2026-04-29 | — | — | EP | claimed |
| US-12512514-B2 | Electrolyte solution for lithium-sulfur secondary battery and lithium-sulfur secondary battery comprising same | LG ENERGY SOLUTION, LTD. (KR) | 2025-12-30 | — | — | US | claimed |
| US-20230355500-A1 | TOPICAL COMPOSITION | LILIGER LTD (IL) | 2023-11-09 | — | — | US | claimed |
| US-20230130655-A1 | ELECTROLYTE SOLUTION FOR LITHIUM-SULFUR SECONDARY BATTERY AND LITHIUM-SULFUR SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION, LTD. (KR) | 2023-04-27 | — | — | US | claimed |
| EP-4106071-A1 | ELECTROLYTE FOR LITHIUM-SULFUR SECONDARY BATTERY AND LITHIUM-SULFUR SECONDARY BATTERY COMPRISING SAME | LG Energy Solution, Ltd. (KR) | 2022-12-21 | — | — | EP | claimed |
| CN-115398699-A | Electrolyte for lithium-sulfur secondary battery and lithium-sulfur secondary battery comprising same | 株式会社LG新能源 | 2022-11-25 | — | — | CN | claimed |
| WO-2022149876-A1 | ELECTROLYTE FOR LITHIUM-SULFUR SECONDARY BATTERY AND LITHIUM-SULFUR SECONDARY BATTERY COMPRISING SAME | 주식회사 엘지에너지솔루션 | 2022-07-14 | — | — | WO | claimed |
| CN-109075393-B | Electrolyte for lithium-sulfur battery and lithium-sulfur battery comprising same | 株式会社LG化学 | 2022-02-18 | — | — | CN | claimed |
| EP-3136475-B1 | LITHIUM METAL BATTERY | SAMSUNG ELECTRONICS CO LTD (KR) | 2021-09-22 | — | — | EP | claimed |
| CN-108028430-B | Electrolyte for lithium-sulfur battery and lithium-sulfur battery comprising same | 株式会社LG化学 | 2021-09-14 | — | — | CN | claimed |
| US-5785994-A | OSMOTIC DOSAGE FORM FOR CONTROLLED DRUG RELEASE | ALZA CORPORATION (US) | 1998-07-28 | — | — | US | claimed |
| US-5646181-A | ORGANIC NITRITE COMPOUNDS | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1997-07-08 | — | — | US | claimed |
| US-5489610-A | TREATING CONDITIONS SUCH AS ANGINA PECTORIS, ISCHEMIC DISEASES, CONGESTIVE HEART FAILURE, CONTROLLING HYPERTENSION AND IMPOTENCE IN MALE PATIENTS | RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1996-02-06 | — | — | US | claimed |
| EP-0546038-B1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY | ALZA CORP (US) | 1994-07-27 | — | — | EP | claimed |
| US-5232705-A | Hypotensive agents. vasodilators | ALZA CORPORATION (US) | 1993-08-03 | — | — | US | claimed |
| EP-0546038-A1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY. | ALZA CORP (US) | 1993-06-16 | — | — | EP | claimed |
| EP-0538335-A1 | DOSAGE FORM FOR ADMINISTERING A DRUG TO EFFECT CIRCADIAN THERAPY. | ALZA CORP (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992004011-A1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY | ALZA CORPORATION (US) | 1992-03-19 | — | — | WO | claimed |
| WO-1992000729-A1 | DOSAGE FORM FOR ADMINISTERING A DRUG TO EFFECT CIRCADIAN THERAPY | ALZA CORPORATION (US) | 1992-01-23 | — | — | WO | claimed |
| EP-0302697-A1 | Inhibition of polymerization of unsaturated acid in the vapor phase | ROHM AND HAAS COMPANY (US) | 1989-02-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12512514-B2 | Electrolyte solution for lithium-sulfur secondary battery and lithium-sulfur secondary battery comprising same | LEF1, CLCN2, LITAF | KMT2A 1949/4885CA1 1947/4885CA2 450/4885 |
| US-20230355500-A1 | TOPICAL COMPOSITION | NOS1, NOS3, NOS2 | KMT2A 4669/4885CA1 4735/4885CA2 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.